Ipsen (LTS:0MH6) ROE % Adjusted to Book Value: 2.26% (As of Dec. 2025)


LTS:0MH6 Ipsen SA LTS:0MH6
94 GF Score
Price €170.25
GF Value €133.53
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ipsen ROE % Adjusted to Book Value?

Ipsen LTS:0MH6 -0.29% 94 ROE % Adjusted to Book Value is 2.26% as of Dec. 2025. GuruFocus rates LTS:0MH6 with a GF Score™ of 94/100 and a GF Value™ of €133.53 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Ipsen's ROE % for the quarter that ended in Dec. 2025 was 5.11%. Ipsen's PB Ratio for the quarter that ended in Dec. 2025 was 2.26. Ipsen's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 2.26%.

Ipsen ROE % Adjusted to Book Value Related Terms

Ipsen ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Ipsen's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipsen ROE % Adjusted to Book Value Chart

Ipsen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.93 8.54 7.68 3.95 4.61

Ipsen Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.62 5.04 2.53 8.02 2.26

LTS:0MH6 vs ZTS, UTHR, VTRS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ipsen ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipsen's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Ipsen's ROE % Adjusted to Book Value falls into.


LTS:0MH6
94GF Score
Ipsen SA LTS:0MH6
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ipsen ROE % Adjusted to Book Value Calculation

Ipsen's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=10.41% / 2.26
=4.61%

Ipsen's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=5.11% / 2.26
=2.26%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 2.26% mean?
Ipsen (LTS:0MH6) has a ROE % Adjusted to Book Value of 2.26% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Ipsen and its competitors.
Is Ipsen's ROE % Adjusted to Book Value too high?
Ipsen's current ROE % Adjusted to Book Value is 2.26%. Overall, Ipsen has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipsen's ROE % Adjusted to Book Value compare to ZTS and UTHR?
Ipsen's ROE % Adjusted to Book Value of 2.26% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Ipsen and its competitors. Ipsen's current ROE % Adjusted to Book Value is 2.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Based on GuruFocus' analysis, Ipsen (LTS:0MH6) is currently considered Modestly Overvalued. The stock's GF Value™ is €133.53, compared to a current price of €170.25 — trading 27.5% above its estimated fair value. The current ROE % Adjusted to Book Value is 2.26%. Ipsen's overall GF Score™ is 94/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Ipsen (LTS:0MH6), the current ROE % Adjusted to Book Value is 2.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipsen (LTS:0MH6) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €170.25 is trading 27.5% above its estimated GF Value™ of €133.53. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for LTS:0MH6:

  • ROE % Adjusted to Book Value: 2.26%
  • GF Value™: €133.53 vs. price of €170.25 (27.5% above fair value)
  • GF Score™: 94/100 with 7 warning signs

No single metric tells the full story. See the LTS:0MH6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
94GF Score

Get the complete analysis for LTS:0MH6

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€170.25
Price
€133.53
GF Value